Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 12,609 · FY2024 18,890 — 3-yr total 31,499
Pharmaceutical importer/distributor active in the Georgian market.
| Line item | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | 81 | 2,549 | 13,265 | 19,328 | nmf |
| Net Cash used in Investing Activities | 261 | 707 | 1,263 | 855 | +48.5% |
| Free Cash Flow (OCF − Capex proxy) | 342 | 1,842 | 12,002 | 18,473 | nmf |
| Net Cash from Financing Activities | 369 | 1,144 | 12,608 | 18,374 | nmf |
| Net Change in Cash (before FX) | 27 | 699 | 606 | 100 | +53.7% |
| Effect of FX on Cash | 18 | 31 | 8 | 169 | nmf |
| Net Change in Cash (incl. FX) | 45 | 667 | 614 | 69 | nmf |
| Cash at Beginning of Year | 0 | 45 | 713 | 99 | +47.8% |
| Cash at End of Year | 45 | 713 | 99 | 29 | -13.2% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →